ERV29 Antibody

What is ERp29 and what is its primary function in cellular biology?

ERp29 (Endoplasmic Reticulum Protein 29) is a resident protein of the endoplasmic reticulum that plays a crucial role in the processing of secretory proteins. Unlike many ER proteins, it does not appear to function as a disulfide isomerase. Instead, it participates in protein folding within the endoplasmic reticulum, contributing to proper secretory protein processing . ERp29 is also known by several alternative names including ERP28, ERp31, C12orf8, and Endoplasmic reticulum resident protein 28/29/31. The protein is evolutionarily conserved across mammalian species, suggesting its fundamental importance in cellular function.

What experimental applications are suitable for ERp29 antibodies?

ERp29 antibodies, such as the rabbit polyclonal antibody ab137670, have been validated for multiple experimental applications including:

• Western Blotting (WB)

• Immunohistochemistry on paraffin sections (IHC-P)

• Immunocytochemistry/Immunofluorescence (ICC/IF)

These applications enable researchers to investigate ERp29 expression, localization, and interactions in various experimental contexts. The versatility of these applications allows researchers to employ complementary techniques to validate their findings across different experimental platforms.

What is the molecular weight of ERp29 in different species?

The predicted molecular weight of ERp29 varies slightly between species:

These differences should be considered when interpreting Western blot results across species . The molecular weight can also vary slightly depending on post-translational modifications which may occur in different cell types or under different physiological conditions.

What are the optimal dilution conditions for ERp29 antibody in Western blotting?

For Western blotting applications, the ERp29 antibody (ab137670) has been successfully used at a dilution of 1/1000. This dilution has demonstrated effective detection of ERp29 in various human cell lines including 293T, A431, and H1299 whole cell lysates (30 μg protein loading), as well as in mouse brain whole cell lysate (50 μg protein loading) . Researchers should consider performing a dilution series during initial optimization experiments to determine the ideal concentration for their specific sample type and detection system.

How should I validate the specificity of ERp29 antibody in my experimental system?

Validating antibody specificity is critical for ensuring reliable experimental results. For ERp29 antibody validation, consider these methodological approaches:

• Positive and negative controls: Use cell lines or tissues known to express or lack ERp29 expression

• Knockdown/knockout validation: Compare staining between wild-type and ERp29 knockdown/knockout samples

• Peptide competition assay: Pre-incubate antibody with immunizing peptide to block specific binding

• Multi-antibody approach: Use multiple antibodies targeting different epitopes of ERp29

• Molecular weight confirmation: Verify that detected bands match the predicted molecular weight (29 kDa for human, 26 kDa for mouse)

Implementation of at least two validation methods is recommended to ensure confidence in antibody specificity, particularly for publications and critical experiments.

What sample preparation methods are recommended for ERp29 Western blotting?

For optimal Western blot results with ERp29 antibody, sample preparation should include:

• Lysis buffer selection: Use RIPA or NP-40 based buffers containing protease inhibitors

• Protein denaturation: Heat samples at 95°C for 5 minutes in loading buffer containing SDS and a reducing agent

• Gel selection: 12% SDS-PAGE gels have been successfully used for ERp29 detection

• Loading amount: 30-50 μg of total protein is typically sufficient for detection in most cell and tissue lysates

• Transfer conditions: Use standard wet transfer protocols with PVDF or nitrocellulose membranes

Adherence to these methodological details helps ensure consistent and reproducible detection of ERp29 in Western blotting experiments.

How can I use ERp29 antibody to investigate protein folding mechanisms in the endoplasmic reticulum?

ERp29 participates in the folding of proteins within the endoplasmic reticulum , making its antibody a valuable tool for investigating ER protein folding mechanisms. Advanced research approaches include:

• Co-immunoprecipitation studies: Use ERp29 antibody to pull down ERp29 and identify interacting folding partners

• Proximity labeling: Combine with BioID or APEX approaches to map the ERp29 interactome

• Subcellular fractionation: Isolate ER fractions and analyze ERp29 associations with folding substrates

• Conditional knockout systems: Investigate folding defects in ERp29-depleted cells

• Stress response experiments: Monitor ERp29 levels and interactions under conditions of ER stress

What are the considerations for using ERp29 antibody in immunohistochemistry applications?

For successful immunohistochemistry with ERp29 antibody, researchers should consider:

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective

• Blocking parameters: Use 5-10% normal serum from the same species as the secondary antibody

• Primary antibody incubation: Overnight incubation at 4°C often yields optimal staining

• Detection system selection: Both ABC and polymer-based detection systems are compatible

• Counterstaining: Hematoxylin provides good nuclear contrast without obscuring ERp29 staining

The ERp29 antibody (ab137670) has been validated for IHC-P applications , making it suitable for investigating ERp29 expression patterns in tissue sections from various organs and disease states.

How does ERp29 expression change under conditions of ER stress, and how can this be monitored?

ERp29, as an ER resident protein involved in secretory protein processing , may exhibit altered expression during ER stress. Advanced methodological approaches to investigate this include:

• Time-course experiments: Monitor ERp29 levels at various timepoints after induction of ER stress with tunicamycin, thapsigargin, or DTT

• Western blotting quantification: Use ERp29 antibody alongside other ER stress markers (BiP/GRP78, CHOP, XBP1)

• qRT-PCR correlation: Compare protein levels detected by antibody with mRNA expression changes

• Subcellular redistribution: Use immunofluorescence to track potential changes in ERp29 localization

• Polysome profiling: Assess translational regulation of ERp29 during stress conditions

This multi-method approach provides comprehensive insights into ERp29 regulation during ER stress, potentially revealing novel functions in stress response pathways.

What might cause multiple bands or unexpected band sizes when using ERp29 antibody in Western blotting?

When encountering multiple bands or unexpected band sizes with ERp29 antibody, consider these technical explanations and solutions:

• Post-translational modifications: ERp29 may undergo glycosylation or phosphorylation

• Proteolytic degradation: Include fresh protease inhibitors in lysis buffers

• Isoform detection: ERp29 has multiple alternative names (ERp28, ERp31) , potentially indicating isoforms

• Cross-reactivity: Validate specificity using knockdown controls

• Sample preparation issues: Ensure complete denaturation of samples

Expected band sizes are 29 kDa for human samples and 26 kDa for mouse samples . Significant deviations from these sizes warrant further investigation through validation experiments.

How can I optimize ERp29 immunofluorescence staining to achieve better signal-to-noise ratio?

For improved signal-to-noise ratio in ERp29 immunofluorescence experiments:

• Fixation optimization: Compare paraformaldehyde (4%) with methanol fixation

• Permeabilization conditions: Test different detergents (0.1-0.5% Triton X-100, 0.1% Saponin) and incubation times

• Blocking enhancement: Increase blocking time (2-3 hours) and consider adding 0.1-0.2% fish gelatin to blocking solution

• Antibody concentration titration: Perform a dilution series to identify optimal antibody concentration

• Secondary antibody selection: Use highly cross-adsorbed secondary antibodies to minimize background

The ab137670 antibody has been validated for ICC/IF applications , and these optimization steps can help achieve clear visualization of ERp29 localization within the endoplasmic reticulum.

What controls should be included in ERp29 antibody experiments?

Proper experimental controls are essential for antibody-based experiments. For ERp29 antibody work, include:

• Positive control: Cell lines known to express ERp29 (293T, A431, H1299 for human; brain tissue for mouse)

• Negative control: Samples with ERp29 knockdown/knockout or tissues known to lack expression

• Primary antibody omission: Assess secondary antibody non-specific binding

• Isotype control: Use non-specific IgG from the same species as the primary antibody

• Loading control: Include detection of housekeeping proteins (β-actin, GAPDH) or total protein staining

Implementing these controls enhances data reliability and facilitates troubleshooting if unexpected results occur.

How can de novo antibody design approaches be applied to develop improved ERp29 antibodies?

Recent advances in computational antibody design could potentially be applied to develop enhanced ERp29 antibodies. Methodological considerations include:

• Structure-based epitope selection: Identify optimal epitopes based on ERp29 structure

• Computational antibody generation: Apply methods like GaluxDesign for targeted ERp29 binding

• Library screening approaches: Use yeast display libraries with 10^6 candidate sequences

• Binding affinity optimization: Select for higher affinity and specificity through directed evolution

• Developability assessment: Evaluate productivity, stability, and polyreactivity

These advanced approaches could yield ERp29 antibodies with improved specificity, affinity, and performance across multiple applications, enhancing research capabilities.

What are the considerations for using ERp29 antibodies in multiplex immunoassays?

For incorporating ERp29 antibodies into multiplex detection systems, researchers should consider:

• Antibody labeling strategy: Choose compatible fluorophores or enzymatic labels

• Cross-reactivity assessment: Test for potential cross-reactivity with other antibodies in the panel

• Signal balancing: Optimize concentration of each antibody to achieve balanced signal intensity

• Sequential versus simultaneous detection: Determine optimal staining protocol

• Spectral unmixing requirements: Consider spectral overlap when selecting fluorophores

Multiplex approaches allow simultaneous investigation of ERp29 alongside other proteins of interest, providing insights into co-localization, co-expression, or pathway relationships.

What are emerging research areas where ERp29 antibodies are providing new insights?

ERp29 antibodies are enabling advances in several research domains:

• ER stress and unfolded protein response: Investigating ERp29's role in maintaining ER homeostasis

• Secretory pathway modulation: Understanding ERp29's contribution to protein secretion efficiency

• Disease-associated protein misfolding: Exploring ERp29 involvement in protein aggregation disorders

• Cancer biology: Examining altered ERp29 expression in various malignancies

• Developmental biology: Studying ERp29's role during cellular differentiation and organogenesis

The continued development and validation of ERp29 antibodies will facilitate deeper exploration of these research areas, potentially revealing novel therapeutic targets and biological mechanisms.

How might advances in antibody engineering and AI-driven design impact future ERp29 antibody development?

The future of ERp29 antibody development may be shaped by several emerging technologies:

• AI-driven antibody design: Models like GaluxDesign v3 may enable precision engineering of ERp29-specific antibodies

• Single-domain antibody formats: Development of camelid VHH or shark VNAR antibodies against ERp29

• Site-specific conjugation strategies: Creation of homogeneous ERp29 antibody-conjugates

• Structure-guided epitope targeting: Design of antibodies against functional domains of ERp29

• Machine learning for sequence optimization: Use of models like those described in to improve antibody properties